Affiliation:
1. The Second Affiliated Hospital of Nanchang University
Abstract
Abstract
Aims
To investigate the association between thyroid hormone sensitivity and metabolic dysfunction-associated fatty liver disease (MAFLD) with elevated liver enzymes in the euthyroid populations.
Methods
A total of 3929 euthyroid adults from the Second Affiliated Hospital of Nanchang University were included in this study. Thyroid hormone sensitivity indices were calculated by thyroid feedback quantile-based index (TFQI), TSH index (TSHI) and thyrotropin thyroxine resistance index (TT4RI). Associations between thyroid hormones sensitivities and risk of MAFLD, MAFLD with elevated liver enzymes, MAFLD with elevated free fatty acid (FFAs) were assessed with logistic regression.
Results
After adjustment for multiple risk factors, odd ratios (ORs) of the fourth versus the first TFQIFT4 quartile for MAFLD, MAFLD with elevated liver enzymes, and MAFLD with elevated FFAs were 1.778 (95% CI 1.378, 2.293), 1.466 (1.105, 1.945), and 1.936 (1.479, 2.534), respectively (all p < 0.001). Per 1 SD in TFQIFT4, ORs increased 2.27 (95% CI 1.74, 2.97) for MAFLD, 2.05 (1.51, 2.78) for MAFLD with elevated liver enzymes, and 2.43 (1.82, 3.24) for MAFLD with elevated FFAs. The other sensitivity to thyroid hormones indices showed similar associations for MAFLD and MAFLD with elevated liver enzymes.
Conclusions
Impaired sensitivity to thyroid hormone in euthyroid population is associated with MAFLD, MAFLD with elevated liver enzymes, T2DM, hyperuricemia, elevated liver enzymes, and MAFLD with elevated FFAs. TFQIFT4, TFQIFT3, TSHI and TT4RI can be used as new indicators for predicting MAFLD and MAFLD with elevated liver enzymes, While TFQIFT3 performed better than the other three indexes.
Publisher
Research Square Platform LLC
Reference29 articles.
1. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The lancet. Gastroenterology & hepatology. (2022)7:851–861.
2. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement;Eslam M;Journal of hepatology,2020
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L,Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md.). (2016)64:73–84.
4. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches;Schuppan D;Journal of gastroenterology and hepatology,2013
5. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system;Reddy JK;Annual review of nutrition.,2001